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Aim: Idiotype, the unique part of immunoglobulin molecule expressed on the surface of B-cells, represents a specific antigen for 
vaccination against lymphoma. We have developed a rapid method for immunoglobulin variable fragments cloning, assembling and 
expression of recombinant idiotype protein in Escherichia coli. Methods: PCR with specially designed panel of primers was used 
for direct amplification of variable regions of tumor immunoglobulin. Overlapping extension PCR, restriction and ligation was 
applied for assembling and cloning of vaccine construction. Idiotype protein was purified by metal-chelate chromatography. Results: 
Methods of idiotype cloning from lymphoma cells and production of recombinant protein were developed and optimized. Several 
samples of idiotypic proteins originating from B-cell lines and lymphoma patients were produced. Conclusion: The proposed 
method of vaccine production is relatively cheap, not very laborious and requires as long as 6–7 week to perform. The expressed 
protein was soluble, did not accumulate in inclusion bodies and harvested at sufficient for vaccination quantity and concentration.
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Development of anti-cancer vaccination has still 
been limited by the low number of known tumor-
associated antigens that might be used as targets for 
directional immunization. Cells of lymphomas express 
antigen-specific receptors, surface immunoglobulin 
for B cell lymphomas and T cell receptor for lympho-
mas of the T lineage. As tumor has a clonal origin, all 
cells of lymphoma carry identical immunoglobulin 
or TCR receptor on their surface. Therefore, variable 
domains of immunoglobulin (idiotype) can be used 
as specific antigen for anti-idiotypic vaccination.
The clinical studies of anti-idiotypic vaccination have 
started since 1992 when Ron Levy and Larry Kwak (Stan-
ford University, USA) first vaccinated follicular lymphoma 
patients with tumor-derived immunoglobulin [1]. In the 
last decade numerous clinical trials were performed 
using hybridoma-prodused immunoglobulin harvested 
from cell supernatant and showed immunological re-
sponse and clinical benefit in vaccinated patients [2, 3].
While preparation of individual Ig using rescue hy-
bridoma method is time-consuming and expensive, 
further studies came to production of recombinant vac-
cine by cloning variable Ig fragments from DNA of tumor 
cells [4]. Several methods for expression of Id-protein 
have been used, including insect cell culture [5], plants 
[6–8], bacteria E. coli [9, 10], or cell-free expression 
system [11, 12]. These methods require some efforts 
for purification of protein. Id-protein can be conjugated 
with immunogenic carrier protein, such as KLH, and ad-
ministrated to the patient with adjuvant, usually GM-CSF 
[13]. Alternatively, production of Id-pulsed autologous 
dendritic cells (DC) can be used for enhancing anti-
tumor immune response [14, 2]. Finally, the simplest 
strategy is nude DNA vaccines [15–17].
Most methods of recombinant idiotype protein 
expression and all methods of DNA Id-vaccine utilize 
cloning of heavy and light immunoglobulin chains vari-
able fragments and their assembling into single chain 
variable fragment (scFv) [18]. The most difficult problem 
in that procedure is PCR amplification of the whole vari-
able regions of both immunoglobulin chains due to great 
number of VH, VK and VL gene segments and their oc-
casional usage in Ig genes rearrangement. To solve this 
problem, a sophisticated method of anchored-PCR for 
amplification 5’-end of cDNA was developed [19]. This 
method implies addition of oligo-dG-tail to the 5’-end 
of cDNA by enzyme Tdt, first amplification with anchor-
primer and subsequent semi-nested amplification 
with internal primer to the proximal constant region. 
Anchored-PCR requires optimization to be performed 
properly. In original publication of F. Osterroth only 
amplification of IgM heavy chain and IgK light chain 
was described [19]. Several studies describe amplifica-
tion of V-regions with specific primers and assembling 
of scFv [20, 21] for defined immunoglobulin or hybri-
doma, which is not suitable for broad applications.
In this study, we performed design of specific 
primers for direct amplification of all possible variable 
regions of IgM, IgG heavy chains, IgK, IgL light chains 
without loss or addition of amino acids, and describe 
method of cloning, assembling scFv and expression 
of idiotypic protein in bacteria E. coli. As well, we re-
alized the ability to add fusion gene of co-stimulator 
to the construction in the N-part of the protein. Recom-
binant Id-protein obtained in this way may be used for 
direct vaccination or loading of DC.
MATERIALS AND METHODS
Cell lines, patient samples, RNA isolation and 
cDNA synthesis. Four immunoglobulin expressing 
lymphoma cell lines IM-9, Daudi, RPMI1788 and Na-
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malva were used for idiotype cloning. Cells were grown 
in RPMI-1640 medium with 10% FBS and 2 mM gluta-
mine. 1–5 × 106 cells were collected, washed with PBS 
and lysed for RNA extraction. Tumor cells from patients 
were obtained from bone marrow, lymph node biopsy 
or ascitic fluid containing more than 80% of malignant 
lymphoma cells by histological and/or immunopheno-
typing analysis. Material from three pediatric patients 
was used in this study, ascitic fluid from patient 1 with 
Burkitt’s lymphoma, tumor lymph node biopsy from 
patient 2 with diffuse large B-cell lymphoma and tumor 
lymph node biopsy from patient 3 with Burkitt’s lym-
phoma. Tissue was disrupted in 2 mL of saline solution 
with 50 μL of RNAlater (Qiagen) to generate cell suspen-
sion. RNA was isolated TRI reagent (Sigma) according 
to the manufacture’s instruction dissolved in sterile water, 
measured by spectrophotometry and immediately stored 
at −80°C. 1 μg of total RNA was used for cDNA synthesis 
with MMLV reverse transcriptase and Oligo-dT.
PCR amplification of Ig variable fragments. PCR 
amplification was performed for each gene in a semi-
nested manner with a specially designed primers panel 
(details in Results). All primers were designed to unify 
PCR conditions at 60 °C. PCR reaction was performed 
in 30 μL with 12.5 pmol of each primer, 200 μM dNTP, 
1.5 mM MgCl2 and 1U HF DNA-Polymerase (mix of Pfu 
and Taq-polymerases, Primetech, Belarus). We used 
30 cycles of PCR, but the number of cycles may be re-
duced to 20 cycles for the first step of amplification 
to minimize probability of nucleotide replacements 
due to DNA-polymerase errors. PCR products were 
examined by 1.5% agarose gel. For the first step of am-
plification heteroduplex analysis in polyacrylamide gel 
was applied to discriminate homoduplexes (mono-
clonal PCR products) from a smear of slowly moving 
heteroduplexes (derived from polyclonal lymphocytes). 
This step is useful only for tumor biopsy from patients 
and not essential for B-cell lines. PCR products were 
denatured for 5 min at 95 °C and rapidly cooled down 
to +4 °C to induce duplex formation. Size separation 
of the generated homoduplexes and heteroduplexes 
was obtained in 8% non-denaturing polyacrylamide gel.
Molecular cloning and sequencing. Assembled 
scFv fragment was excised from agarose gel, purified 
by QIAquick Gel Extraction Kit (Qiagen) and directly li-
gated into pTZ57R/T vector through T/A overlapping us-
ing InsTAclone PCR Cloning Kit (Fermentas). E. coli XL1-
blue was transformed by calcium chloride method with 
ligation mix. Selection of blue and white recombinant 
clones was performed on S-Gal®/LB Agar Blend (Sig-
ma-Aldrich) with ampicillin. Plasmid DNA was recovered 
from 5–10 clones with EasyPrep Pro Plasmid Miniprep 
Kit (PerkinElmer). Sequence of insertion was done with 
plasmid primers pUC19-seq-F GTTTTCCCAGTCAC-
GACGTT and pUC19-seq-R TGTGGAATTGTGAGCGGA-
TA. Sequence reaction was done using BigDye® Termi-
nator v3.1 Cycle Sequencing Kit (Applied Biosystems) 
on genetic analyzer ABI PRISM 3130. Plasmids with 
correct sequence were digested with NdeI and HindIII, 
SalI or NotI restrictases (Fermentas) and subcloned 
into pET24b (Novagen) expression vector. Before final 
transformation sequence was checked by sequencing 
with primers pET24b_F TGTGAGCGGATAACAATTCC 
and pET24b_R TTCCTTTCGGGCTTTGTTAG.
Expression and purification of protein. Re-
combinant expression vectors with inserted idiotype 
pET24b-scFv were introduced into bacteria E. coli BL21-
CodonPlus (DE3)-RIPL and selected by chlorampheni-
col and kanamycin. Night culture was diluted 1:200 with 
TB medium, containing 30 mkg/ml kanamycin and 
cultured at 37 °C until culture reached OD A600 0.6–0.8. 
Expression was induced by cultivation with 0.5 mM IPTG 
at 31 °C for 3 hours. Cells were harvested, resuspended 
in 20 mM Tris-НСI, 0.4 mM PMSF, 0.5 M NaCl (рН 8.0) 
buffer and disrupted with EmulsiFlex-C5 homogenizer 
or treated with ultrasound three times for 20 s on ice. 
Cell debris were separated by 20 min centrifugation 
18 500 g and supernatant collected for electrophoresis 
and protein purification.
Purification of protein was performed by metal-
chelate chromatography on columns with Ni-NTA 
agarose. Binding of protein on the columns, washing 
and elution was performed in denaturing conditions 
with 6M urea. Column was washed by 20 mM imidazole 
solution and protein was eluted by 300 mM imidazole. 
Urea, salts and imidazole were removed by dialysis 
[22]. Cell lysate, fraction of column wash and pure 
protein were analyzed in 12% SDS-PAGE (Laemmli 
method) and stained with Coomassie Brilliant Blue.
Western blot analysis. Samples of 10 ng of puri-
fied protein were run in 12% SDS-PAGE with positive 
and negative controls. Transfer was done on Semi-dry 
transport unit (Amersham Biosciences) onto nitrocel-
lulose filter. Filter was pre-stained with reversible dye 
Ponceau S (Sigma-Aldrich) to check protein bands. 
Blot was blocked with Western Blocker™ Solution 
(Sigma-Aldrich), washed with Tween-TBS and treated 
with primary monoclonal mouse antibodies to 6-His tag 
(Abcam). Secondary antibodies were rabbit polyclonal 
to mouse IgG conjugated to HRP (Abcam). Finally blot 
was stained with diaminobenzene and documented with 
ChemiDoc™ XRS+ System (Bio-Rad) in visible light. 
Defined 6His-tagged protein with molecular weight 
of 17 kDa was used as a positive control. Lines of filter 
with separated tested and control proteins were also 
treated with normal mice serum as negative control.
RESULTS
Primers design for PCR-amplification of im-
munoglobulin variable regions. Most human B-cell 
lymphoma express immunoglobulin of the IgM isotype, 
with either kappa or lambda light chain. However, some 
lymphomas express IgG immunoglobulin [23]. To cover 
as many lymphomas as possible, we developed extend-
ed primer panel for all four immunoglobulin chain types: 
IgM, IgG, IgK and IgL. Database of all functional V gene 
segments was collected form http://www.imgt.org web-
site. Immunoglobulin heavy chain V-segments were 
combined by homology into VH1–6 families and aligned 
with AlignX service of Vector NTI 9.0 program package 
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(Invitrogen) and MEGA-4 software. Forward primer was 
designed to the first 7–8 codons of a VH gene segment 
avoiding variable and polymorphic nucleotide near the 
3’end of the primer. Primer design allowed up to 2 mis-
matches with germline sequence. An example of primer 
design for VH1 is shown on Fig. 1.
Fig. 1. Primer design for aligned gene segments of VH1 family. 
Primer sequence is underlined and titled on the top. Variable 
nucleotides are marked as bold blue letters
The same principle was used for forward primes 
of all 6 VH families of IgH, all 3 Vk families of IgK and 
1–5 VL families of IgL gene. For some IgL V-segments 
three or four first codons were excluded from PCR 
amplification to enable optimal primer design. Several 
VL gene segments belonging to VL6,7,8,9 families 
were not included due to their very rare occurrence 
in immunoglobulin molecule.
Two reverse primers were selected for proximal (C1) 
constant region of IgM, IgG, IgK genes for two steps 
of semi-nested PCR amplification of variable Ig domains. 
Distal reverse primer for the first step of PCR is denoted 
as -3’, and proximal primer is denoted as -clon. For IgL 
gene, one distal IGLC-3’ primer was selected for all IGLC 
regions, but two different proximal primers were se-
lected, one for IGLC1 and another for IGLC2–7 constant 
regions. Reverse primers to heavy chain include in the 
cloned fragment a few amino acids (12 a.a. for IgM and 
10 a.a. for IgG) on the 5’ edge of CH1 segments. This 
part of constant region was left intentionally to retain with 
6His-linker two-domain structure of scFv. The schematic 
positions of all primers are shown on Fig. 2 and primers 
sequences are shown in Table 1.
Detection of immunoglobulin expression on tu-
mor cells. Diagnostics of lymphoma includes immu-
nohpenotypic analysis by flow cytometry, including 
surface immunoglobulin M or G and kappa/lambda light 
chain detection. Patient’s 1 lymphoma cells expressed 
IgM+/IgK+, patient’s 2 — IgG+/IgK+ and patient’s 3 — 
IgM+/IgL+. We also performed immunophenotypic 
analysis of all B-cell lines kept in our laboratory: REH 
IgH-/IgK-, Raji IgM+/IgK-, IM-9 IgG+/IgK+, Daudi 
IgM+/IgK+, RPMI1788 IgM+/IgL+, Namalva IgM+/IgL+. 
Cell lines REH and Raji were excluded because they 
do not express mature immunoglobulin on cell surface. 
Other cell lines: IM-9, Daudi, RPMI1788 and Namalva 
were used for immunoglobulin V-genes cloning. DNA 
of all samples used in this study was analyzed by PCR 
for clonal IgH gene rearrangements as described in our 
previous publication [24]. This step is not required for 
vaccine production, but may be useful for rapid identi-
fication or verification of V-region and junctional region.
Table 1. Sequences of primers for PCR-amplification of immunoglobulin 
variable regions
Primer name Sequence Position
VH1-5’clon CAGGTGCAGCTGGTGCAGTCTGG forward
VH2-5’clon CAGGTCACCTTGAAGGAGTCTGG forward
VH3-5’clon GAGGTGCAGCTGGTGGAGTCTGG forward
VH4-5’clon CAGGTGCAGCTGCAGGAGTCGGG forward
VH5-5’clon GAGGTGCAGCTGGTGCAGTCTGG forward
VH6-5’clon CAGGTACAGCTGCAGCAGTCAGG forward
Cμ-3’ CTCTCAGGACTGATGGGAAGCC reverse distal
Cμ-clon GGAGACGAGGGGGAAAAG reverse proximal
IgG-3’ GCCTGAGTTCCACGACACC reverse distal
IgG-clon CAGGGGGAAGACCGATGG reverse proximal
Vκ1-5’clon GACATCCAGATGACCCAGTCTCC forward
Vκ2/3-5’clon GATATTGTGATGACCCAGACTCCA forward
IgκC-3’ CCCCTGTTGAAGCTCTTTGT reverse distal
IgκC-clon AGATGGCGGGAAGATGAAG reverse proximal
VL1_(51)_clon CAGTCTGTGTTGACGCAGCCGCCCTC forward
VL1_(36-47)_clon TCTGTGCTGACTCAGCCACCCTC forward
VL1_(40)_clon CAGTCTGTCGTGACGCAGCCGCCCTC forward
VL2-clon TCCGTGTCCGGGTCTCCTGGACAGTC forward
VL3-clon ACTCAGCCACCCTCGGTGTCAGTG forward
VL4-clon TCCTCTGCCTCTGCTTCCCTGGGA forward
VL5-clon CAGCCTGTGCTGACTCAGCC forward
IGLC-3’ GTGTGGCCTTGTTGGCTTG reverse distal
IGLC2-7_clon CGAGGGGGCAGCCTTGGG reverse proximal
IGLC1_clon AGTGACCGTGGGGTTGGCCTTGGG reverse proximal
Fig. 2. Scheme of primers positions and approximate length 
of PCR-products
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Amplification of immunoglobulin variable frag-
ments. PCR reactions were performed with primers 
for identified immunoglobulin chain genes. Separate 
PCR reactions were done for every VH, Vk or VL prim-
ers. Because of similar primer sequence, some PCR 
reactions showed unspecific amplification, which did 
not influence cloning (Fig. 3). PCR reactions of the first 
step which generated clear bands were submitted for 
the second step with proximal reverse primer. Products 
were separated in polyacrylamide gel, marked bands 
of the right size were cut from the gel, DNA eluted and 
sequenced. Sequence finally proved which V-region 
corresponds to expressed immunoglobulin. For Daudi 
cell line, immunoglobulin heavy chain was VH3, and 
kappa chain was Vk1. Eluted DNA of the right sequence 
was used as a template for assembling of scFv.
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Fig. 3. A. Agarose gel identification of the first step PCR products 
of IgH and IgK variable regions semi-nested PCR amplification 
of for Daudi cell line. B. Assembling of scFv by OE-PCR for Daudi 
cell line in triplicates; primers for cloning are indicated.
Assembling and cloning of scFv. Two variable 
fragments of heavy and light immunoglobulin chains 
was further fused together by 6-histidine linker and 
cloned by two different restriction sites into the ex-
pression vector. For that purpose, both fragments 
were reamplified with primers including restriction 
sites, start- and stop-codons and 6His-tag. Restriction 
sites were chosen according to their presence in the 
MCS of pET24b vector and absence in the consensus 
regions of used immunoglobulin genes parts. The 
last principle was not fully applicable due to non-
predictable sequence of junctional (CDR3) regions 
and after hypermutation throughout V-regions. To the 
beginning of construction the site for NdeI restrictase 
containing start-codon (CATATG) was added. The end 
of scFv was designed in two alternative ways. First, 
the sequence of scFv in open frame finished with SalI 
or HindIII restriction site. This site may be used to add 
co-stimulator gene in fusion to scFv as SalI/HindIII — 
NotI fragment. If no fusion co-stimulator gene is used, 
transcription will terminate at the pET24b internal 
stop codon after addition of another 6-His tag to the 
expressing protein. Second, the sequence of scFv 
ends with stop-codon and NotI site. Design of several 
alternative restriction sites was advi sedly redundant for 
a case of casual appearance on of the restriction site 
sequence inside the segments and to make it possible 
to clone construction in other vectors. Overall scheme 
of genetic construction is shown on Fig. 4.
Overlap extension PCR (OE-PCR) was used 
to fuse variable fragments of heavy and light immuno-
globulin chains. For that, 6 histidine codons — CAC-
CATCATCATCACCAC were added to 5’end of V-clon 
primers of IgK/IgL and reverse complement sequence 
to the 5’-end of C-clon primers of IgH. We designed 
different His codons to avoid overlap shift during OE-
PCR. The sequences of cloning primers are shown 
in Table 2.
Each of the purified DNA fragments from the previ-
ous step was amplified with appropriate pair of clon-
ing primers. Identical quantity of both PCR products 
was mixed and subjected to 10 cycles of PCR without 
primers, applying annealing temperature 55 °C and 
high-fidelity polymerase. Immediately afterwards an-
other part of PCR mix containing flanking primers and 
20 cycles of PCR proceeded with Tan= 65 °C. Fused 
scFv construct was separated from non-used frag-
Fig. 4. Scheme of scFv constructions. Restriction site 1 (Rs1) — NdeI, Rs2 — SalI or HindIII, Rs3 — NotI
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ments in agarose gel (Fig. 3 b), bands of DNA were 
excised, eluted and directly cloned to pTZ57R/T vector. 
After proving of the right sequence, scFv was sub-
cloned into pET24b by restriction and ligation.
Table 2. Sequences of primers for scFv assembling and cloning
Forward cloning primers
VH1-5’-XbaI GCG TCT AGA CAT ATG CAG GTG CAG CTG GTG CAG TCT GG
VH2-5’-XbaI GCG TCT AGA CAT ATG CAG GTC ACC TTG AAG GAG TCT GG
VH3-5’-XbaI GCG TCT AGA CAT ATG GAG GTG CAG CTG GTG GAG TCT GG
VH4-5’-XbaI GCG TCT AGA CAT ATG CAG GTG CAG CTG CAG GAG TCG GG
VH5-5’-XbaI GCG TCT AGA CAT ATG GAG GTG CAG CTG GTG CAG TCT GG
VH6-5’-XbaI GCG TCT AGA CAT ATG CAG GTA CAG CTG CAG CAG TCA GG
Reverse open frame primers
IgκC-SalI GCG GTC GAC AGA TGG CGG GAA GAT GAA G
IgκC-HindIII GCG AAG CTT AGA TGG CGG GAA GAT GAA G
IGLC2-7_SalI GCG GTC GAC CGA GGG GGC AGC CTT GGG
IGLC2-7_
HindIII 
GCG AAG CTT CGA GGG GGC AGC CTT GGG
IGLC1_SalI CGC GTC GAC AGT GAC CGT GGG GTT GGC CTT GGG
IGLC1_HindIII GCG AAG CTT AGT GAC CGT GGG GTT GGC CTT GGG 
Reverse termination primers
IGLC2-7_
stop_NotI 
GCG GC GGC CGC TTA CGA GGG GGC AGC CTT GGG
IGLC1_stop_
NotI 
GCG GC GGC CGC TTA AGT GAC CGT GGG GTT GGC CTT GGG 
IgκC_stop_
NotI 
GCG GC GGC CGC TTA AGA TGG CGG GAA GAT GAA G
Forward 6-his tag primers
Vk1-5’tag CAC CAT CAT CAT CAC CAC GAC ATC CAG ATG ACC CAG TCT CC 
Vk2/3-5’tag CAC CAT CAT CAT CAC CAC GAT ATT GTG ATG ACC CAG ACT CCA 
VL1_(51)_tag CAC CAT CAT CAT CAC CAC CAG TCT GTG TTG ACG CAG CCG
VL1_(36-
47)_tag
CAC CAT CAT CAT CAC CAC TCT GTG CTG ACT CAGC CA
VL1_(40)_tag CAC CAT CAT CAT CAC CAC CAG TCT GTC GTG ACG CAG CCG
VL2-tag CAC CAT CAT CAT CAC CAC TCC GTG TCC GGG TCT CCT GGA
VL3-tag CAC CAT CAT CAT CAC CAC ACT CAG CCA CCC TCG GTG TCA GTG 
VL4-tag CAC CAT CAT CAT CAC CAC TCC TCT GCC TCT GCT TCC CTG GGA 
VL5-tag CAC CAT CAT CAT CAC CAC CAG CCT GTG CTG ACT CAG CC
Reverse 6-his tag primers
Cg-tag GTG GTG ATG ATG ATG GTG CAG GGG GAA GAC CGA TGG
Cμ-tag GTG GTG ATG ATG ATG GTG GGA GAC GAG GGG GAA AAG 
PVXCP cloning primers
PVXCP-F-SalI GCG GTC GAC ATG TCA GCA CCA GCT AGC ACA A
PVXCP-F-
HindIII 
GCG AAG CTT ATG TCA GCA CCA GCT AGC ACA A
PVXCP-R-
NotI 
G CGC GGC CGC TTA TGG TGG TGG TAG AGT GAC AAC
For cell lines Daudi, IM-9, RPMI1788 and patients 
scFv was clones as NdeI — HindIII fragments with 
additional plasmid 6-His tag at the C-end of protein. 
Construction of scFv failed for RPMI1788 cell line 
because of appearance of NdeI restriction site in-
side IGLV2–23 gene segment. For the last cell line, 
Namalva, two kinds of construction were made. First 
ended with the SalI restriction site without stop-codon, 
which result in addition of 6-His at the 3’-end of scFv, 
and second terminated close to the NotI site. We also 
constructed chimeric construction of patient’s 1 id-
iotype and co-stimulating gene of Potato virus X coat 
protein (PVXCP) [25] (Table 2).
Expression and purification of idiotype pro-
tein. Totally, six idiotype proteins were expressed 
and purified as described in Materials and Methods. 
Several experiments were employed to optimize 
induction of protein expression with IPTG. Optimal 
expression was detected after induction of E. coli 
with 0.4 — 0.5 mM IPTG for 3 hours. SDS-PAGE 
of cellular protein extracts demonstrated appearance 
of clear band with an expected molecular weight 
of 28–30 kDa (Fig. 5).
Our preliminary experiments showed that purifi-
cation of proteins on Ni-NTA column binding in non-
denaturing conditions was confronted with some prob-
lems: infirm binding of protein in the column and heavy 
contamination of eluted fraction with high-molecular 
weight bacterial proteins. Chromatography of idiotype 
proteins in denaturing conditions (6M urea) provided 
firm and specific binding to the Ni-NTA columns and 
very reliable purification of target protein. All proteins 
except form scFv went through the column, and after 
washing, target protein was eluted.
— 50 kDa
— 30 kDa
— 20 kDa
28 kDa —
1 2 3
Fig. 5. Induction of Daudi-scFv protein expression in E. coli 
induced by IPTG. 1 — before induction; 2 — after induction; 
3 — molecular weight marker
We compared expression of two scFv constructs 
of Namalva. First, encoding 263 amino acids, was 
cloned as NdeI-stop-NotI fragment. Second, encoding 
278 amino acids, was cloned as NdeI-SalI fragment 
and included N-tail 6-His tag encoded by the vector. 
Both proteins were successfully purified (Fig. 6), which 
means that additional N-terminate 6-His tag did not 
influence purification efficacy and can be removed. 
Idiotype proteins were also identified by Western blot 
analysis using antibodies to 6His-tag. Testing of id-
iotype protein for IM-9 cell line showed stained band 
of the right size 28 kDa (Fig. 7).
— 50 kDa
— 30 kDa
— 40 kDa
— 25 kDa
— 28 kDa
— 15 kDa
— 10 kDa
1 4 72 5 83 6 99 10 11
Fig. 6. Fractions of Namalva scFv protein purification. 1 — cell 
after induction; 2 — supernatant of cell lysate; 3 — lysate passed 
through the column; 4 — wash of Ni-NTA columns with 20 mM im-
idazole; 5–8 — fractions of protein elution with 300 mM imidazole; 
9 — molecular weight marker; 10 — pure scFv protein (SalI-
6-His); 11 — pure scFv protein (stop-NotI)
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Fig. 7. Western blot of idiotype protein for IM-9 cell line. Lines: 
1 — IM-9 protein + anti-6His-AB 1:1000; 2 — IM-9 protein + anti-
6His-AB 1:500; 3 — IM-9 protein + mouse serum; 4 — control 
protein + anti-6His-AB 1:1000; 5 — control protein + mouse serum
DISCUSSION
Series of studies and clinical trials have provided 
convincing evidence of biological and clinical efficacy 
as well as of clinical benefit of soluble scFv protein 
for anti-idiotype vaccination [3, 13, 26, 27]. How-
ever, three Phase III randomized clinical trials have 
failed to achieve their main end points, presumably 
because of imperfect study design or its conduction 
[28–30]. At present, customized idiotypic vaccination 
yet remains a non-approved, experimental approach 
for patients with lymphoma. Taking into account that 
hybridoma-derived Id-protein is time consuming and 
difficult to produce new trials should probably employ 
‘second-generation vaccine’ including recombinant 
protein, fusion to gene-costimulator and usage 
of DC for vaccine delivery [4, 28].
The aim of this study was development of a method 
for the simplest, fast idiotype vaccine production, fea-
sible in basic laboratory of medical centre. Besides the 
labor and time criteria, method of vaccine production 
must be applicable to a wide range of patients and dif-
ferent mature B-cell malignances. To realize this aim, 
two main difficulties have to be overcome: cloning 
of individual, highly diverse immunoglobulin variable 
fragments and convenient expression system with 
protein purification.
Primers were designed for PCR amplification of four 
immunoglobulin chains: immunoglobulin M and G heavy 
chains and kappa- and lambda light chains to cover 
most (>95%) B-cell lymphomas [23]. cDNA was used 
as a template to allow application of reverse primers 
to the proximal part of constant region, which possible 
only after RNA splicing and make it possible to unify 
primer set. We refused anchored PCR as a complication 
of the method. Leader sequence of V-segment is not 
required in bacterial expression system, and does not 
contain essential antigen determinants for vaccine. 
Start codon is included in primers for the cloning. Po-
sitions of the primers make it possible to amplify the 
whole sequence of variable regions without loss or ad-
dition of amino acids except from 6His-tag in the middle 
of construction. The use of consensus reverse primer 
and similarity between forward (V-specific) primers 
gives some nonspecific amplification, originating from 
cross-annealing of V-specific primers. But, two steps 
of PCR, heteroduplex analysis followed by purification 
of DNA fragment in polyacrylamide gel and sequenc-
ing make identification of clonal rearrangements very 
reliable, even if no data about immunoglobulin expres-
sion was obtained by immunophenotyping. Eluted from 
gel DNA bands was used for amplification with cloning 
and 6-His tagged primers, accomplishing preparation 
of both fragments of scFv with 3 rounds of PCR.
Protein produced by hybridoma, transfected mam-
malian or insect cells takes month or more to prepare. 
Therefore, choice of the expression system, providing 
abundant, inexpensive and easily purified vaccine 
was between bacteria and plants. Attractive method 
of utilizing tobacco plants for individualized idiotype 
vaccine production was proposed by A. McCormick 
and colleagues [6–8, 31]. However, not all clinical 
laboratories have facilities for plants culturing, and this 
method require additional 2 weeks for plant infection 
and accumulation of protein [6].
Expression of protein in bacteria may by the most 
suitable method, but it also have some serious draw-
backs. First, there is some uncertainty if protein of pro-
karyotic expression is correctly folded and if absence 
of glycosylation and an inability to form stable disulfide 
bonds may influence antigen properties of idiotype. 
Retention of original protein structure depends on the 
methods of purification. In this study, we made certain 
that denaturation of protein is necessary for chromato-
graphic purification. In denaturing conditions original 
bacterial tertiary structure of protein was destroyed 
and protein was refolded during dialysis. If there is any 
influence of idiotypic proteins conformation their ability 
to act as an antigen will be defined after immunological 
assay of these vaccines. There are some evidences, that 
scFv proteins expressed in bacteria retain the antigen-
binding capacity of original cell-born antibody [32, 21]. 
However, regardless of tertiary structure of expressed 
and purified protein, it may be used for loading of DC, 
as we are going to do in our further experience of vac-
cine testing and clinical trial. Second problem with 
expression of protein in bacteria is that protein may 
accumulate in insoluble form of inclusion bodies. It may 
be solved by denaturing of protein and its refolding 
during dialysis. Some studies described that accumula-
tion of allogenic protein in inclusion bodies in bacteria 
is provoked by overexpression of protein and increased 
temperature [33, 34]. In our experience that problem 
was not essential and all proteins were soluble.
In conclusion, we elaborated rapid method of the 
idiotypic vaccine production by PCR-based cloning 
and expression of scFv in E. coli. Our study was initially 
intended for DC loading with E. coli derived protein, 
as the most safe and effective way of anti-idiotype im-
munization.
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